Clear cell sarcoma of the kidney (CCSK) is the second most common renal malignancy in children. The prognosis is poorer in CCSK than in Wilms' tumor, and multimodal treatment including surgery, intensive chemotherapy, and radiation is required to improve the outcome for children with CCSK. Histological evaluation is required for the diagnosis. However, biopsies of tumors to obtain diagnostic specimens are not routinely performed because of the risk of spreading tumor cells during the procedure. Recently, internal tandem duplication (ITD) of BCOR has been recognized as a genetic hallmark of CCSK. We herein established a novel BCOR-ITD-specific polymerase chain reaction method with well-designed primers, and then performed a liquid biopsy for cell-free DNA (cfDNA) obtained from plasma of three children with nonmetastatic renal tumors (stage II) and from one control. BCOR-ITD was positively detected in the cfDNA of two cases, both of which were later diagnosed as CCSK based on histological feature of the resected tumor specimen, while it was not detected for a normal control and a patient diagnosed with Wilms' tumor. Our study is the first one of preoperative circulating tumor DNA assay in pediatric renal tumors. The liquid biopsy method enables less invasive, preoperative diagnosis of CCSK with no risk of tumor spillage, which can avoid iatrogenic upstaging.
| INTRODUCTION
Clear cell sarcoma of the kidney (CCSK) is the second most common renal malignancy in children, comprising 2%-5% of pediatric renal tumors. In the past, the prognosis was poorer in patients with CCSK than in patients with Wilms' tumor. 1, 2 Current multimodal treatment including surgery, intensive chemotherapy, and radiation has achieved improved outcomes for CCSK in children, but the survival probability for younger patients and metastatic cases still remains poor. 2, 3 The imaging findings of CCSK are indistinguishable from those of other renal tumors, such as Wilms' tumor and malignant rhabdoid tumor of the kidney (MRTK), despite the disparate treatment requirements. Thus, histological evaluation is required for a diagnosis. 
| MATERIALS AND METHODS

| Patients and samples
This study included three cases consecutively diagnosed as renal tumors at the National Center for Child Health and Development. The details of the clinical characteristics, imaging findings, and pathological features are shown in Figure 1 and Supporting Information Table S1 .
In addition, one healthy control was included.
For UPN1 and UPN2, upfront total tumor resection and nephrectomy were performed. UPN1 was histologically diagnosed as stage II CCSK based on findings of vascular extension of the tumor in the nephrectomy specimen. UPN2 was diagnosed as a stage II Wilms'
tumor without anaplastic histology. The tumor in UPN3 was huge and extended to the vena cava. We therefore decided to initiate preoperative chemotherapy with weekly dactinomycin and vincristine. After 10 weeks of treatment, the tumor shrank and a nephrectomy with total tumor resection was successfully performed. The tumor specimen showed extensive necrotic tissue, but a small viable fraction of the specimen showed typical CCSK features.
| IRB approval
This study was approved by the ethics committee at the National Center for Child Health and Development (#1035), and written informed consent was obtained from the patients or parents.
| Plasma isolation
For plasma isolation, 5 mL peripheral blood was collected before treatment using an EDTA blood collection tube. Plasma was isolated from the blood sample by performing 2000 rpm centrifugation for 10 minutes and carefully obtaining the plasma. For long-term storage, the plasma was stored at −80 C in 1 mL aliquots prior to DNA extraction.
| Genomic and cfDNA extraction
Genomic DNA extraction from frozen tissue was described in a previous report. 4 CfDNA containing ctDNA was purified from 1 mL stored plasma from patients or healthy individual using Maxwell RSC cfDNA 
| BCOR-ITD detection
The primers were designed to detect the duplicated consensus sequence of BCOR-ITD rather than to amplify the normal BCOR sequence (Figure 2A ). The primer sequences were 5 0 -ACGAAATTCA-GACTCTGCT-3 0 (forward) and 5 0 -TCGTGAATTCCACCAGAT-3
(reverse) 0 . The PCR product was subcloned into pGEM-T and confirmed by sequencing analysis. Genomic PCR primers for tumor tissues were described in a previous report. The average fragment size of cfDNA, which derives from chromatosomes (nucleosome core particle plus linker histone), is 167 bp, while the duplication size of BCOR-ITD is approximately 100 bp and includes a consensus region common to all BCOR-ITD positive CCSK. 4 ,5 Therefore, we designed a primer set specifically for BCOR-ITD detection in that region. A well-designed primer set does not amplify the normal BCOR sequence, because it is designed to run in the opposite direction inside the common sequence.
As a standard strategy for pediatric renal tumors, the Children's Oncology Group (COG) has adopted upfront nephrectomy followed by chemotherapy with the aim of obtaining an early and accurate histological diagnosis. In some cases, however, a total tumor resection is difficult because of the invasion of the tumor into major arteries or other organs as seen in UPN3. Moreover, there is a danger of rupture during surgery, and the International Society of Paediatric Oncology (SIOP) advocates preoperative chemotherapy to mitigate this risk. 16 However, this approach renders pathological diagnosis difficult by exposing specimens to cytotoxic agents and can delay implementing an intensive strategy in the event the tumor is identified as CCSK or MRTK. BCOR-ITD is most specific for CCSK of all the renal tumors, and detecting this genomic Moreover, previous reports showed that BCOR-ITD was also detected in soft tissue undifferentiated round cell sarcomas, 17 primitive myxoid mesenchymal tumors of infancy, 18 high-grade neuroepithelial tumors of the central nervous system, 19 high-grade endometrial stromal sarcomas, 20 and undifferentiated uterine sarcomas. 21 Detection of BCOR-ITD in ctDNA is useful for the molecular diagnosis of these malignancies. On the other hand, it should be noted that our liquid biopsy would be expected to miss the minority of CCSK with other translocations, such as YWHAE-NUTM2B 6 and BCOR-CCNB3.
7
Our study included only two cases of CCSK and limited number of control and was therefore unable to confirm the sensitivity/specificity of a liquid biopsy for BCOR-ITD. This is a major limitation of this study, and further investigation using larger cohorts with various stages of malignancy is required. Advances in genomic technology will also doubtlessly improve the detectability of ctDNA.
In conclusion, we demonstrate that well-designed primers can be 
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